Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals Target Price
See Regeneron Pharmaceuticals's analyst price targets ($840) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$930.67
Average Target Price
$837.28
10% downside
10% downside25 analysts in the last 4 months
High: $1030 | Low: $730
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-10-30 | Robert W. BairdBrian Skorney | $875 | 6% downside |  |
| 2026-10-19 | Piper Sandler | $865 | 7.1% downside | |
| 2026-10-14 | UBS | $978 |  5.1% upside | |
| 2026-10-08 | Raymond JamesChris Raymond | $911 | 2.1% downside | |
| 2026-10-08 | RBC CapitalBrian Abrahams | $810 | 13% downside | |
| 2026-10-07 | Truist Financial | $780 | 16.2% downside | |
| 2026-10-07 | Morgan Stanley | $779 | 16.3% downside | |
| 2026-10-01 | Argus Research | $850 | 8.7% downside | |
| 2026-10-01 | Jefferies | $930 | 0.1% downside | |
| 2026-10-01 | BMO CapitalEvan David Seigerman | $920 | 1.1% downside | |
| 2026-09-10 | HSBCRajesh Kumar | $920 | 1.1% downside | |
| 2026-08-17 | Leerink PartnersDavid Risinger | $824 | 11.5% downside | |
| 2026-08-14 | BernsteinJeffrey Walch | $756 | 18.8% downside | |
| 2026-08-03 | Guggenheim | $1,030 | 10.7% upside | |
| 2026-07-31 | Robert W. Baird | $761 | 18.2% downside | |
| 2026-07-31 | Cantor FitzgeraldCarter Gould | $795 | 14.6% downside | |
| 2026-07-31 | Wells Fargo | $750 | 19.4% downside | |
| 2026-07-31 | Morgan Stanley | $758 | 18.6% downside | |
| 2026-07-31 | RBC Capital | $737 | 20.8% downside | |
| 2026-07-21 | GuggenheimYatin Suneja | $1,000 | 7.4% upside | |
| 2026-07-09 | Piper SandlerBiren Amin | $854 | 8.2% downside | |
| 2026-07-08 | Morgan StanleyTerence Flynn | $730 | 21.6% downside | |
| 2026-07-07 | Truist Financial | $769 | 17.4% downside | |
| 2026-07-06 | HSBC | $800 | 14% downside | |
| 2026-07-06 | Cantor Fitzgerald | $750 | 19.4% downside | |
| 2026-05-19 | Canaccord GenuityJohn Newman | $875 | 6% downside | |
| 2026-05-18 | Evercore ISI | $825 | 11.4% downside | |
| 2026-05-18 | Wolfe ResearchAlexandria Hammond | $860 | 7.6% downside | |
| 2026-05-18 | RBC Capital | $707 | 24% downside | |
| 2026-05-18 | Piper Sandler | $855 | 8.1% downside | |
| 2026-05-18 | BMO Capital | $730 | 21.6% downside | |
| 2026-05-18 | Truist Financial | $778 | 16.4% downside | |
| 2026-05-18 | Leerink PartnersMarket Perform | $641 | 31.1% downside | |
| 2026-05-01 | GuggenheimYatin Suneja | $995 | 6.9% upside | |
| 2026-04-30 | Truist Financial | $796 | 14.5% downside | |
| 2026-04-30 | Morgan StanleyTerence Flynn | $788 | 15.3% downside | |
| 2026-04-30 | Barclays | $917 | 1.5% downside | |
| 2026-04-22 | Raymond JamesChris Raymond | $910 | 2.2% downside | |
| 2026-04-10 | Morgan Stanley | $796 | 14.5% downside | |
| 2026-04-08 | Bernstein | $921 | 1% downside | |
| 2026-03-09 | Truist FinancialGreg Renza | $818 | 12.1% downside | |
| 2026-03-06 | BarclaysEliana Merle | $923 | 0.8% downside | |
| 2026-03-02 | RBC CapitalBrian Abrahams | $765 | 17.8% downside | |
| 2026-02-09 | Guggenheim | $975 | 4.8% upside | |
| 2026-02-02 | Cantor FitzgeraldCarter Gould | $800 | 14% downside | |
| 2026-02-02 | Robert W. BairdBrian Skorney | $742 | 20.3% downside | |
| 2026-02-02 | Tudor PickeringWilliam Pickering | $925 | 0.6% downside | |
| 2026-02-02 | Oppenheimer | $865 | 7.1% downside | |
| 2026-02-01 | Morgan StanleyTerence Flynn | $769 | 17.4% downside | |
| 2026-01-30 | Raymond James | $870 | 6.5% downside | |